Regulus Therapeutics Inc. Soars 90% On Hep C Treatment News

Regulus Therapeutics Inc. RGLS announced a breakthrough Wednesday in its hepatitus C treatment which sent the stock soaring 90 percent.

The company clained “that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").”

The company’s press release indicated that the demonstration is “a significant milestone in Regulus' history, and represents a key achievement under our 'Clinical Map Initiative'," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus.  

"We believe these interim data are exceptional and provide strong evidence to support the rapid advancement of RG-101 into future clinical studies, while presenting a clear opportunity for a potentially disruptive therapy to the current HCV treatment paradigm," according to Xanthopoulos.

Regulus Therapeutics Inc. recently traded at $12.85, up 89.81 percent.